Hansoh Pharmaceutical Group Company Limited

SZSC:3692 Stock Report

Market Cap: HK$106.5b

Hansoh Pharmaceutical Group Past Earnings Performance

Past criteria checks 5/6

Hansoh Pharmaceutical Group has been growing earnings at an average annual rate of 9.4%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 5.5% per year. Hansoh Pharmaceutical Group's return on equity is 16.9%, and it has net margins of 39%.

Key information

9.4%

Earnings growth rate

7.5%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate5.5%
Return on equity16.9%
Net Margin39.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Hansoh Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSC:3692 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2412,0984,7144,3162,364
31 Mar 2411,1013,9964,2782,231
31 Dec 2310,1043,2784,2412,097
30 Sep 239,7822,9264,2071,990
30 Jun 239,4592,5754,1721,884
31 Mar 239,4212,5794,1601,789
31 Dec 229,3822,5844,1481,693
30 Sep 229,6752,6524,2661,771
30 Jun 229,9682,7204,3851,849
31 Mar 229,9522,7174,3781,823
31 Dec 219,9352,7134,3711,797
30 Sep 219,5242,6754,1991,630
30 Jun 219,1122,6384,0271,463
31 Mar 218,9012,6033,9451,358
31 Dec 208,6902,5693,8621,252
30 Sep 208,3772,5263,7511,146
30 Jun 208,0632,4833,6411,039
31 Mar 208,3732,5203,8431,080
31 Dec 198,6832,5574,0441,121
30 Sep 198,6152,3574,1581,099
30 Jun 198,5482,1574,2711,077
31 Mar 198,1352,0304,135979
31 Dec 187,7221,9033,999881
31 Dec 176,1861,5953,318576
31 Dec 165,4331,4762,916403

Quality Earnings: 3692 has high quality earnings.

Growing Profit Margin: 3692's current net profit margins (39%) are higher than last year (27.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 3692's earnings have grown by 9.4% per year over the past 5 years.

Accelerating Growth: 3692's earnings growth over the past year (83.1%) exceeds its 5-year average (9.4% per year).

Earnings vs Industry: 3692 earnings growth over the past year (83.1%) exceeded the Pharmaceuticals industry 9.4%.


Return on Equity

High ROE: 3692's Return on Equity (16.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 07:52
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hansoh Pharmaceutical Group Company Limited is covered by 32 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sharon ShiBOCI Research Ltd.
Bo LiBofA Global Research
Jin ZhangChina International Capital Corporation Limited